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Abstract
Mutations of mitochondrial DNA (mtDNA) are associated with a wide spectrum of disorders encompassing the
myopathies, encephalopathies and cardiomyopathies, in addition to organ specific presentations such as diabetes mellitus
and deafness. The pathogenesis of mtDNA mutations is not fully understood although it is assumed that their final common
pathway involves impaired oxidative phosphorylation. The identification of a specific respiratory chain defect (complex I
deficiency) in Parkinson’s disease (PD) 10 years ago focused attention on the aetiological and pathogenetic roles that
mitochondria may play in neurodegenerative diseases. There is evidence now emerging that mtDNA abnormalities may
determine the complex I defect in a proportion of PD patients and it may prove possible to use biochemical analysis of
platelet and cybrid complex I function to identify those that lie within this group. Respiratory chain defects of a different
pattern have been identified in Huntington’s disease (HD) (complex II/III deficiency) and Friedreich’s ataxia (FA) complex
I^III deficiency). In both these disorders, the mitochondrial abnormality is secondary to the primary nuclear mutation:CAG
repeat in the huntingtin gene in HD, and GAA repeat in the frataxin gene in FA. Nevertheless, it appears that the
mitochondrion may be the target of the biochemical defects that are the consequence of these mutations. There is a close and
reciprocal relationship between respiratory chain dysfunction and free radical generation, and there is evidence for oxidative
stress and damage in PD, HD and FA, which together with the mitochondrial defect may result in cell damage. Impaired
oxidative phosphorylation and free radical generation may independently adversely affect the maintenance of mitochondrial
transmembrane potential (vim). A fall in vim is an early event (preceding nuclear fragmentation) in the apoptotic pathway.
It is possible therefore that mitochondrial dysfunction in the neurodegenerative disorders may result in a fall in the apoptotic
threshold of neurones which, in some, may be sufficient to induce cell death whilst, in others, additional factors may be
required. In any event, mitochondria present an important target for future strategies for ‘neuroprotection’ to prevent or
retard neurodegeneration. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Numerous disorders have now been associated
with mutations of mitochondrial DNA (mtDNA)
[1]. Many of these inborn errors of mitochondrial
metabolism involve the central nervous system as
encephalopathies or encephalomyopathies, probably
re£ecting the dependence of neurones on oxidative
phosphorylation for energy requirements. The last
few years have seen the emergence of increasing evi-
dence to suggest that neurodegenerative diseases per
se may involve mitochondrial dysfunction in patho-
0005-2728 / 98 / $19.00 ß 1998 Elsevier Science B.V. All rights reserved.
PII: S 0 0 0 5 - 2 7 2 8 ( 9 8 ) 0 0 1 1 5 - 7
* Fax: +44 (171) 431 1577;
E-mail : schapira@rfhsm.ac.uk
BBABIO 44659 30-7-98
Biochimica et Biophysica Acta 1366 (1998) 225^233
genesis. In some, e.g. Huntington’s disease (HD),
Friedreich’s ataxia (FA), any mitochondrial abnor-
mality must be secondary to the respective mutation,
whilst in others, e.g. Parkinson’s disease (PD), Alz-
heimer’s disease, the position is less certain. This re-
view focuses on the role of respiratory chain defects
in the aetiology and pathogenesis of PD, HD and
FA.
2. Mitochondrial DNA structure and function
Each mitochondrion contains 2^10 molecules of
DNA. MtDNA is a circular double stranded mol-
ecule of 16.5 kb comprising a heavy (H) and a
light (L) chain but without any histone coat.
MtDNA encodes a full complement of 22 transfer
RNAs (tRNAs) and 12S and 16S ribosomal RNAs
in addition to 13 proteins, all of which are part
of the respiratory chain and oxidative phosphoryl-
ation (OXPHOS) system. MtDNA is dependent
upon the cell nucleus for encoding its replication,
transcription, translation, repair and regulatory fac-
tors.
Human mtDNA is inherited through the maternal
line alone as spermatozoan mitochondria do not en-
ter the ovum at fertilisation. It would be anticipated,
therefore, that disorders caused by a mutation of
mtDNA would exhibit maternal inheritance. This is
indeed seen, although only in a minority of cases.
Patients with mtDNA deletions, the most common
mtDNA mutation, appear as sporadic cases; even
40% of patients with the 11 778-bp Leber’s hereditary
optic neuropathy mutation have no family history
[2]. Thus, whilst maternal inheritance may alert the
clinician to a mtDNA defect, such a pattern will not
necessarily be apparent in the majority of those with
mtDNA mutations.
3. Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative
disorder with a lifetime risk of 1 in 40. It is charac-
terised clinically by bradykinesia, rigidity and tremor
and pathologically by the death of dopaminergic
neurones in the substantia nigra. The cause or causes
of PD are unknown but major advances have re-
cently been made in our understanding of aetiology
and pathogenesis.
A mutation (A53T) in the K-synuclein gene of one
Italian and three Greek families with autosomal
dominant parkinsonism has recently been reported
[3]. A di¡erent mutation in the same gene of an un-
related German PD pedigree has also just been iden-
ti¢ed [4]. Although the A53T K-synuclein mutation
has not been identi¢ed in sporadic PD, this does not
exclude other mutations in this gene being relevant in
PD [5]. The mechanisms by which a mutation in such
a widely expressed protein as K-synuclein induces
selective cell death of nigral dopaminergic neurones
promises to provide insight into pathogenetic path-
ways relevant to PD and other neurodegenerative
diseases.
Although the K-synuclein gene mutation is inher-
ited in autosomal dominant fashion, the range of age
of onset of PD in a¡ected families is the same as that
in sporadic PD, i.e. third to seventh decades [6] (L.
Golbe, personal communication). This variation in
age of onset is seen irrespective of geographic loca-
tion, i.e. it is seen in both the American and Italian
arms of the major pedigree. This observation sug-
gests that there are modifying factors in the pene-
trance of the K-synuclein mutation, which are prob-
ably genetic.
Abnormalities of mitochondrial function, and ox-
idative phosphorylation (OXPHOS) in particular,
have been identi¢ed in neurodegenerative diseases
(see [7] for review). In PD the type and speci¢city
of mitochondrial defect contrasts with those seen in
Alzheimer’s disease, HD and FA and there is now
evidence emerging that mitochondria, and mtDNA
in particular, may play a role in both aetiology and
pathogenesis (see below). The presence of a defect of
complex I activity in platelets in PD patients suggests
a systemic cause which may be genetically or envi-
ronmentally determined.
Complex I de¢ciency in PD brain was ¢rst de-
scribed in 1989 [8] and provided a direct biochemical
link between MPTP parkinsonism and the idiopathic
disease. Numerous studies have followed to help
understand the cause of the complex I defect and
its relationship, if any, to the aetiology and patho-
genesis of PD. Early work focused on the anatomic
and disease speci¢city of the mitochondrial abnor-
mality (see [9] for review). Using post mortem brain
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homogenates, no de¢ciency was identi¢ed in cortex,
cerebellum, caudate, putamen, tegmentum, globus
pallidus or, subsequently, cingulate cortex or sub-
stantia innominata [10]. Interestingly, an identical
distribution was found for a signi¢cant reduction in
reduced glutathione (GSH) [10,11]. The substantia
innominata is predominantly cholinergic but is also
involved in degeneration in PD. The ¢ndings of de-
creased complex I activity and GSH concentrations
suggest that they do not contribute to either choli-
nergic cell death or Lewy body formation in this
area. The latter proposition is also supported by nor-
mal complex I function and GSH levels in the cingu-
late cortex of patients with ‘dementia with Lewy
bodies’ ^ an area with a particularly high concentra-
tion of Lewy bodies. Thus it would seem that mito-
chondrial dysfunction and oxidative stress are linked
both to each other and to the PD substantia nigra
within the brain.
Patients with multiple system atrophy (MSA) have
severe dopaminergic cell death in the substantia nigra
and present with core clinical features similar to idi-
opathic PD. MSA patients are given L-DOPA for
symptomatic relief in doses similar to, or greater
than, PD patients. Analyses of mitochondrial func-
tion in substantia nigra and other brain areas in
MSA have not identi¢ed any defect [12,13]. These
observations also address the question as to whether
the complex I de¢ciency in PD is simply a result of
neuronal degeneration. The absence of any defect in
MSA, in the presence of severe neuronal loss, indi-
cates that the complex I abnormality is not simply a
re£ection of cell death.
OXPHOS function has also been studied in skel-
etal muscle and platelets of PD patients. In vivo 31P
magnetic resonance spectroscopy of muscle in PD
has given con£icting results: the ¢rst study showed
no defect [14] whilst the second suggested de¢cient
OXPHOS [15]. Likewise, analysis by polarography
and enzyme activities has given normal results or
multiple OXPHOS defects, sometimes with exceed-
ingly low values (see [9] for review). In contrast, re-
sults from analysis of PD platelets show more con-
sistency. Whilst platelet homogenates in PD show no
de¢ciency [16], the great majority of studies using
puri¢ed platelet mitochondria show an isolated com-
plex I defect (see [16] for review) [17].
We have studied 25 PD patients for platelet OX-
PHOS activity and shown a 16% defect speci¢c for
complex I [18]. However, there was signi¢cant over-
lap between the PD patients and controls such that
the assay was too insensitive to serve as a diagnostic
test. Nevertheless, there was a signi¢cant proportion
of PD patients with complex I activities s 1 S.D.
below the control mean. We have hypothesised that
the PD patients with the lowest platelet complex I
activity are those of the PD population most likely to
carry any putative mtDNA mutation.
In order to address the cause of the complex I
de¢ciency in PD patients we and others have used
genomic transplantation studies [19,20]. King and
Attardi pioneered a cell cybrid system for the inves-
tigation of mtDNA mutations [21]. This involves the
use of b0 (mtDNA-less) cells which have been devel-
oped from a parent cell line by exposure to ethidium
bromide through serial passage. The b0 cells can sur-
vive and grow in medium enriched with pyruvate and
uridine. b0 cells serve as recipients for donor
mtDNA, thereby placing the donor mtDNA in a
novel nuclear environment. This allows the structural
and functional consequences of a mtDNA mutation
to be investigated in isolation, i.e. without the com-
pounding e¡ects of any nuclear in£uence [22^24].
Platelets contain mitochondria and mtDNA but no
cell nucleus and thus serve as ideal sources for
mtDNA in fusion studies with mtDNA-less (b0) cells.
The presence of a complex I defect in PD platelets
makes them particularly relevant in these studies.
PD patients were preselected for their low platelet
complex I activity (s 1 S.D. below control mean).
These patients had typical primary PD and no pos-
itive family history. The platelet complex I defect was
reproducible over time [19]. Platelets from these pa-
tients were fused with A549 b0 cells and grown in
mixed culture in medium to select for successfully
fused cells (cybrids). Complex I activities in the PD
cybrids were signi¢cantly reduced by 25% (P = 0.007)
[19]. As the only remnant of the PD platelets in these
cybrids was their mtDNA, the complex I defect in
both PD platelets and the cybrids must be caused by
a defect of mtDNA. Furthermore, there was a high
correlation between platelet complex I and the cor-
responding patient’s cybrid complex I activities
(r = 0.86, P6 0.001). The combination of these two
indices allowed a more sensitive and speci¢c discrim-
ination between control and PD patients. The fact
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that these two parameters had such a high correla-
tion coe⁄cient also indicates that the mtDNA en-
coded subunits (the only factor common to both
groups) are critical in determining complex I func-
tion.
MtDNA mutations are thought to segregate ran-
domly on cell division. Clonal analysis should there-
fore result in a series of lines with a range of mutant
mtDNA loads. In a series of experiments using plate-
lets with a total 15% A3243G mtDNA mutant load,
we created clones with a range of 0^95% mutant
loads. Defects in complex I and complex IV activities
occurred in clones with a mutant load in excess of
85%. Based on these results and those of others [23^
26] one can predict that cloning of a cell line with a
mtDNA mutation will produce a spectrum of lines
with a large range of respiratory chain activities. One
of the PD cybrid lines was selected at random for
extensive cloning. Sub-clones were examined histo-
chemically for complex IV (cytochrome oxidase,
COX) activity, immunohistochemically with mono-
clonal antibodies to a mtDNA encoded subunit of
COX I (COI), functionally with JC-1 to assess mito-
chondrial membrane potential (vim), and enzymati-
cally for complex I^IV activities. Clonal cybrid lines
with the same nuclear background and a spectrum of
the A3243G mtDNA mutation were studied in par-
allel for comparison. COX histochemistry showed a
heterogeneous intercellular pattern in both the PD
and A3243G clones, i.e. some cells stained normally
whilst others were COX negative. This contrasted
with the control clones in which all cells were COX
positive. Likewise, binding of the mtDNA encoded
COI subunit of COX showed intercellular variability
as did JC-1 ^ indicating a spectrum of both func-
tional mtDNA and vim in the clonal lines. Complex
I and complex IV activities varied signi¢cantly
amongst both the PD and A3243G clones. The PD
clones (n = 16) showed a mean 25% decrease in com-
plex I (P6 0.005) and a 20% decrease in complex IV
(P6 0.005) activities. The results in the PD clones
paralleled those in the A3243G clones. These results
taken together indicate that a heteroplasmic mtDNA
abnormality underlies the complex I defect in the PD
cases selected.
It is reasonable to assume that the factor causing
platelet complex I de¢ciency in PD is the same as
that causing the mitochondrial abnormality in sub-
stantia nigra. The complex I defect may result in
neuronal cell death directly, or contribute to a series
of factors which together compromise viability. The
nigral complex I de¢ciency is estimated at V37%,
but may be more or less severe in neurones or glia.
The former will be more vulnerable to any defect in
view of their dependence on OXPHOS. Loss of vim,
possibly resulting from a permeability transition,
could allow the release of mitochondrial proapop-
totic molecules such as apoptosis inducing factor
[27], and perhaps of cytochrome c, which is required
for caspase activation [28]. These events precede nu-
clear DNA fragmentation and are common to the
apoptosis inducing pathways of complex I inhibitors
and free radicals [29,30] (T. Seaton, personal commu-
nication). The mitochondrial complex I defect in PD
substantia nigra could result in reduced vim both
directly via a decrease in ATP production resulting
from impaired OXPHOS, and indirectly through in-
creased free radical generation. Complex I inhibition
is known to induce the generation of superoxide rad-
icals [31]. Thus the mtDNA induced complex I de¢-
ciency in PD could render cells, and neurones in
particular, susceptible to apoptotic cell death (see
Fig. 1).
The identi¢cation of the mtDNA abnormalities
determining the complex I de¢ciency in PD may
not be straightforward. Although a heteroplasmic
mtDNA mutation seems possible, it is also conceiv-
able that the responsible mtDNA abnormality is a
Fig. 1.
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mtDNA haplotype that determines a reduction in
complex I which, in turn, results in lowering of
vim and a cell’s threshold to apoptosis.
4. Huntington’s disease
Huntington’s disease (HD) is caused by an expan-
sion of a CAG repeat in the IT15 gene encoding
huntingtin. The CAG repeat size in the normal pop-
ulation is 6^39, whilst expansions in the range 36^
180 are associated with HD. The majority of adult
onset patients have CAG repeats of 40^55. Hunting-
tin is widely expressed in the nervous system and in
all peripheral tissues studied to date. It is found in
neural cell bodies, dendrites and is enriched in nerve
terminals. The function of huntingtin is unknown
but appears to be critical for normal embryological
development [32]. The CAG repeat in mutant hun-
tingtin encodes a polyglutamine stretch which in-
creases binding to a number of proteins including
HAP 1 [33], HIP 1 [34], ubiquitin conjugating en-
zyme [35] and glucose-6-phosphate dehydrogenase
GADPH [36]. Mutant huntingtin appears to cause
HD through a gain of function although the patho-
genetic mechanisms involved in both cell death and
the regional speci¢city of degeneration remain un-
known.
Pathological changes in HD are most pronounced
in the neostriatum with marked atrophy of both cau-
date and putamen, and less severe involvement in the
cerebral cortex. The striosome compartment of the
caudate is a¡ected early and most severely with loss
of spiny neurones projecting to the globus pallidus.
There is relative sparing of NADPH diaphorase pos-
itive striatal neurones. In addition, there is evidence
of loss of large pyramidal cortical neurones. Ultra-
structural examination of HD brain biopsies have
demonstrated abnormalities which have gained in
signi¢cance since the development of animal and tis-
sue culture models of HD. Nuclear inclusions with a
marked increase in nuclear membrane indentation
and an increase in density of nuclear pores have
all been identi¢ed in HD caudate and cortex [37^
41].
Attention has recently focused on direct evidence
for an abnormality of energy metabolism in HD.
Severe defects in the activities of the mitochondrial
respiratory chain have been identi¢ed, speci¢cally
complex II/III (55% de¢ciency) and complex IV
(25% de¢ciency) [42^44]. The respiratory chain defect
is found in caudate and putamen, but not HD cor-
tex, cerebellum or ¢broblasts [44,45]. GAPDH activ-
ity is normal in all areas [44,45], but aconitase is
severely reduced in HD caudate and putamen, less
so in cortex and is normal in cerebellum and ¢bro-
blasts [45]. Aconitase activity is particularly sensitive
to inhibition by superoxide and peroxynitrite (pro-
duced by interaction of superoxide with nitric oxide)
[46]. Taken together, these biochemical abnormal-
ities, which parallel neuropathological changes, sup-
port the hypothesis that excitotoxic cell death is im-
portant in the pathogenesis of HD [45,47]
The pattern, severity and anatomical distribution
of the biochemical abnormalities described have al-
lowed us to generate a hypothesis on their cause and
sequence in HD [45]. Excitotoxicity leads to in-
creased NOc and free radical generation. We propose
that a mild increase in NOc due to low levels of
excitotoxicity will lead to reversible complex IV in-
hibition [48], which in turn will lead to increased O42
generation from the mitochondrial respiratory chain
[49]. The superoxide produced together with
ONOO3, generated from the reaction of O42 with
NOc, will inactivate aconitase. Aconitase is particu-
larly sensitive to inhibition induced by O42 and
ONOO3 in particular [46,50,51]. This situation may
correspond to our observations in the HD cortex.
Higher levels of NOc generated from extensive exci-
totoxicity would lead to even greater levels of O42
and ONOO3 causing inhibition of complexes II/III
[52,53] with free radical damage to DNA lipids and
proteins, including complex IV activity. Although
studies with isolated SMPs suggest complex I and
complex II are the most sensitive components of
the respiratory chain to O42 [54], both studies in
cell culture [55] and in vivo [56] indicate that complex
IV is the most sensitive and ¢rst to be a¡ected by
increased O42 production. This observation, together
with data showing that complexes II and III are the
most sensitive to NOc [45], helps account for our
¢ndings in HD striatum. The levels of inhibition of
aconitase and complexes II/III and IV will relate to
the degree of ONOO3 generation, greatest in the
striatum (severe inhibition of aconitase and complex
II/III), intermediate in the cortex (aconitase only in-
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hibited) and least in the cerebellum (no enzyme in-
hibition detected). As for PD, both the respiratory
chain defect and the generation of free radicals will
be capable of lowering mitochondrial vim and ATP
and thus the threshold for cells to enter the ¢nal
stages of the apoptotic pathway.
A mouse model of HD has been created with a
transgene containing approximately 1 kb of the hu-
man HD promoter region, exon 1, carrying CAG
repeat expansions of 155^156 units, and 262 bp of
intron 1 [57]. Mice from the line with 141^157 CAG
repeats (variability arises through germ line instabil-
ity) exhibit progressive neurological disease from age
two months [58]. Ultrastructural studies of these
mice have identi¢ed neuronal intranuclear inclusions
(NII) in the striatum. The presence of NIIs is also
correlated with frequent indentations of the nuclear
membrane and an increase in nuclear pores. These
changes are almost identical to those found in HD
brains (see above). The NIIs stain positively for hun-
tingtin and ubiquitin [58]. NIIs appear ¢rst in the
cerebral cortex, precede the onset of neurological
features, and spare the NADPH diaphorase positive
neurones of the striatum. The rate of formation of
NII appears largely dependent upon mutant protein
expression levels.
These results indicate that the N-terminal fragment
of huntingtin bearing an abnormal CAG repeat is
su⁄cient to induce a neurological disease in mice
which resembles HD, and induces morphological
changes (NIIs) identical to those found in HD and
which parallel, but antedate, neuropathological
changes.
The stable expression of mutant huntingtin in an
appropriate cell culture line o¡ers a means to inves-
tigate the pathogenetic consequences of CAG expan-
sion. A recent report describes the development of
intracellular protein aggregates in monkey kidney
cells expressing truncated mutant huntingtin [59].
The presence of 44 or 128 CAG repeats resulted in
a redistribution of huntingtin to form perinuclear
aggregates, particularly in those cells expressing a
truncated form of huntingtin, and in those with in-
creasing expansion length. Similar perinuclear aggre-
gates were seen in primary cultures of rat cortical
neurones expressing truncated huntingtin with 128
CAG repeats. Expression of the truncated huntingtin
protein rendered cells more susceptible to apoptosis
than full length huntingtin with the same expansion
length, indicating that the N-terminal fragment of
the protein is more toxic than the holo-protein. Ex-
pression of a huntingtin gene truncated at nucleotide
436 produced intranuclear inclusions in 293T cells
whether there were 15 or 128 CAG repeats. Inter-
estingly, in a mouse model with full length hun-
tingtin and 138 CAG repeats, perinuclear aggre-
gates were present in 1% of cortical neurones but
the mice were asymptomatic at 2 months of age
[59].
5. Friedreich’s ataxia
Friedreich’s ataxia (FA) is an adolescent autoso-
mal recessive disorder with a prevalence of approx-
imately 1 in 50 000. The main clinical features include
progressive ataxia, dysarthria, skeletal deformities,
hypore£exia, pyramidal features and a hypertrophic
cardiomyopathy. Most patients are wheelchair-
bound within 10^15 years of onset and die from pro-
gressive cardiac failure. Pathological processes in FA
primarily a¡ect the central and peripheral nervous
systems and consist of a distal axonopathy of ‘dy-
ing-back’ type a¡ecting the large sensory axons of
the dorsal root ganglia and the spinocerebellar and
pyramidal tracts in the cord, with subsequent loss of
the parent cell bodies.
The molecular genetic defect in 98% of patients
with Friedreich’s ataxia has been identi¢ed as an
unstable GAA triplet repeat in intron 1 of the fra-
taxin (X25) gene resulting in a de¢ciency of frataxin
protein presumably by interfering with RNA proc-
essing. RNA analysis has shown frataxin transcrip-
tion to be highest in the heart, spinal cord and dorsal
root ganglia which correlates well with the pattern of
degeneration observed in the disease.
The function of frataxin is not known. However,
in yeast, deletion of the frataxin gene homologue,
YFH1, which shares a highly conserved C-terminal
domain with frataxin, resulted in severe growth def-
icit on fermentable carbon sources and an inability to
grow on glycerol and ethanol implying a defective
oxidative phosphorylation system. The connection
with mitochondria was strengthened by the presence
of a predicted N-terminal mitochondrial targeting
sequence [60], and the mitochondrial localisation of
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frataxin was con¢rmed using £uorescence micro-
scopy [61,62] and its association with mitochondrial
membranes has recently been con¢rmed [63]. The
role of frataxin in mitochondria is not known, how-
ever several theories have been proposed. The dam-
age and/or loss of mtDNA in yeast lacking the
YFH1 gene have led to the suggestion that frataxin
may be required for mtDNA replication or mainte-
nance [64] although loss of mtDNA is a relatively
common observation in yeast PET mutants [65^68].
Our own studies suggest that mtDNA levels are nor-
mal in FA myocardium (J. Bradley, personal com-
munication). Increased blood lactate levels in pa-
tients with FA support the hypothesis that
oxidative phosphorylation is impaired [69]. There
are con£icting reports that certain mitochondrial en-
zyme activities are decreased in FA cells. These have
included pyruvate dehydrogenase, glutamate dehy-
drogenase, K-ketoglutarate dehydrogenase and com-
plex I^III activities [70^73]. A recent study of two
FA patients found decreased activity of complexes
I^III and aconitase in heart homogenate [74]. Respi-
ratory chain and aconitase activities were studied in
skeletal muscle, lymphocytes and ¢broblasts from a
single FA patient and were found to be normal. The
similarity between a de¢ciency of the antioxidant vi-
tamin E and Friedreich’s ataxia has led to the sug-
gestion that frataxin may be involved in the antiox-
idant defence of the cell [63]. The connection with
abnormal mitochondrial activities is further strength-
ened by the fact that vitamin E de¢ciency in rats
results in markedly decreased complex I and IV ac-
tivities [56] although there is no evidence of large
scale mtDNA abnormalities in this model (unpub-
lished data).
Frataxin has been suggested to be involved in mi-
tochondrial iron metabolism. The evidence for this
comes from the fact that the yeast frataxin homo-
logue, YFH1, has been shown to suppress a mutant
unable to grow on iron limited medium [75]. In ad-
dition in iron rich medium, the high a⁄nity iron
transport system is not usually detectable, but in cells
with a deletion of the YFH1 gene this transport sys-
tem was induced even at high iron concentrations
resulting in increased iron uptake [75]. In this mutant
there is an increase in the mitochondrial iron levels,
but this is not a simple re£ection of the increased
cellular iron levels which implies frataxin may be
involved in mitochondrial iron metabolism [75].
As predicted from Fenton chemistry these cells
were very sensitive to H2O2 treatment and there-
fore are vulnerable to oxidative stress and damage
[75].
Mitochondrial dysfunction caused by deposition of
iron could account for the features of FA. The mi-
tochondrial respiratory chain (MRC) is a major gen-
erator of cellular free radicals. Oxidative stress and
damage would be exacerbated in the presence of free
iron which, by Fenton chemistry, could generate hy-
droxyl ions. The proximity of mtDNA and the MRC
to the site of free radical generation may contribute
to the abnormalities of mtDNA and MRC function
that might result. Neurones and cardiac cells are pri-
marily involved in FA pathology. They are highly
dependant upon oxidative phosphorylation and con-
sequently would be particularly susceptible to defects
of the respiratory chain. However, it is not yet appa-
rent why all neurones are not involved. This could
re£ect di¡erential frataxin expression, with those tis-
sues involved having the highest frataxin expression,
or it may depend on the length and diameter of the
axons that the neuronal perikarya have to support.
The neurones initially a¡ected consistently possess
long large diameter axons. Failure of the cell bodies
to support these axons could result in the distal ax-
onopathy that occurs. In humans, the phenotype ob-
served in the yeast model is unlikely to be compatible
with life. The milder phenotype is likely to re£ect
residual frataxin levels in the patients cells or alter-
native mechanisms performing the frataxin role. Null
mutants for frataxin have not yet been identi¢ed in
humans, possibly because they may be fatal. How-
ever, there is a correlation between genotype and
phenotype with larger GAA repeats being associated
with lower frataxin mRNA and protein expression
and earlier onset and increased severity of the disease
[63,76^78].
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